ReviewWorld journal of gastroenterology2013
Presence of phthalates in gastrointestinal medications: is there a hidden danger?
Review in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Plasticizing Diabetes Care: The Metabolic Threat of Plastic-Associated Endocrine Disruptors and Micro-/Nanoplastics in Clinical Medicine.Current diabetes reports · 2026Review
- Ovarian Toxicity and Epigenetic Mechanisms of Phthalates and Their Metabolites.Current medical science · 2021Review
- Unwitting Accomplices: Endocrine Disruptors Confounding Clinical Care.The Journal of clinical endocrinology and metabolism · 2020Article
- Colitis and Crohn's Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease.Intestinal research · 2020Review
- Impacts of Endocrine Disruptor di-Molecules (Basel, Switzerland) · 2020Article
- 2019 Expert opinion on biological treatment use in inflammatory bowel disease management.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Article
- Dibutyl-phthalate exposure from mesalamine medications and serum thyroid hormones in men.International journal of hygiene and environmental health · 2019Article
- Association between use of phthalate-containing medication and semen quality among men in couples referred for assisted reproduction.Human reproduction (Oxford, England) · 2018Article
- A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease.Environment international · 2016Article
- Management of Inflammatory Bowel Disease During Pregnancy.Digestive diseases and sciences · 2016Review
- Trends in Exposure to Chemicals in Personal Care and Consumer Products.Current environmental health reports · 2015Article
- A perspective on the potential risks of emerging contaminants to human and environmental health.Environmental science and pollution research international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical companies that produce gastrointestinal (GI) medications often utilize phthalates for their ability to localize medication release. Commonly prescribed GI medications that may utilize phthalates are 5-Aminosalicylates, proton pump inhibitors, and pancreatic enzymes. Our understanding of the cumulative health effects of phthalates from medications remains unclear, and there is increasing evidence that phthalates are not harmless. Experimental studies in animals have shown that phthalates, specifically dibutyl phthalate and Di-(2-ethyl-hexyl) phthalate, have the potential to alter and/or inhibit reproductive biology and in utero development. Despite the lack of definitive human data, many cohort and cross-sectional studies demonstrate concerning associations between phthalates and poor health status, specifically developmental problems. Longitudinal studies and studies with larger sample sizes are required to determine whether phthalates actually cause negative health consequences. It is also important that physicians regularly review and discuss with patients the medicinal ingredients in their medications and supplements, specifically in pregnant woman with inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.